B-cell Acute Lymphocytic Leukemia Clinical Trial
Official title:
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06287229 -
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03263208 -
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
|
Phase 1/Phase 2 |